Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.
about
Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal careOxidative stress and Parkinson's diseaseRho family GTPases: key players in neuronal development, neuronal survival, and neurodegenerationCaffeic Acid phenethyl ester: consequences of its hydrophobicity in the oxidative functions and cytokine release by leukocytes.Advantages and Risks of Husbandry and Housing Changes to Improve Animal Wellbeing in a Breeding Colony of Common Marmosets (Callithrix jacchus).An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.NADPH oxidase in brain injury and neurodegenerative disordersCentral nervous system circuits modified in heart failure: pathophysiology and therapeutic implications.Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation.Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease.Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson's disease mice.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes.4-hydroxy-3-methoxy-acetophenone-mediated long-lasting memory recovery, hippocampal neuroprotection, and reduction of glial cell activation after transient global cerebral ischemia in rats.The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.Recovery time after intra-abdominal transmitter placement for telemetric (neuro) physiological measurement in freely moving common marmosets (Callitrix jacchus)
P2860
Q26772285-64BC402C-8FAF-486A-A32D-54058ECB0628Q26798897-08EE7547-2110-4B57-AB60-9D0F38024E24Q27027490-66D4DDA6-1199-48C7-9D01-90431BF1458DQ34182769-01A1C5B8-F19F-4BF4-BCA8-3F6C9E243DABQ35702194-E2C27128-4E15-4BA2-AE75-19AE082D9D1EQ37397401-CD026627-D3B1-4119-B3F3-0090FDE8271DQ37589114-A4FD8054-8B93-40D9-85A4-49C2956AF75EQ38191484-F85B69F9-2D64-493B-8924-0F5E9B8AB8A2Q38942116-C6A2700E-7746-4E4A-8729-6ADF27BD7715Q41357893-8C835059-6416-438E-9870-543B09995B5AQ42263910-DEDAE302-603C-4F2F-BFE1-A563DE76F507Q43679571-E347F4B9-82A5-4D39-A3D7-856A93050761Q46714153-B98B4E43-9952-4B52-AE2A-D8DD0C25B3CFQ47401527-C587434B-90B0-4022-A685-87A0BD099BF0Q48317071-D3780F29-EF68-4347-8D46-CEC50CDFAE8EQ50048940-C079C1CB-4764-413E-BD88-1531F29A84A8Q59321935-87E4B27A-6F3A-4FDD-ACE4-2B0D3F5E732F
P2860
Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@en
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@nl
type
label
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@en
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@nl
prefLabel
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@en
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@nl
P2093
P2860
P1476
Oral treatment with the NADPH ...... sm in the MPTP marmoset model.
@en
P2093
Bert A 't Hart
Ingrid H C H M Philippens
Jacqueline A Wubben
P2860
P2888
P304
P356
10.1007/S11481-013-9450-Z
P50
P577
2013-03-17T00:00:00Z